摘要
手术治疗是可切除食管癌患者首选的治疗手段,但对于部分局部晚期食管癌患者,新辅助治疗使得肿瘤切除成为可能,同时可以降低局部复发和远处转移的风险,基于几项随机临床试验的结果,新辅助治疗能够提高局部晚期可切除食管癌患者的总体生存率。因此新辅助治疗被推荐作为局部晚期可切除食管癌患者的标准治疗。然而,针对不同组织学类型的食管癌患者,新辅助治疗具体的方案仍然存在争议。此外,免疫检查点抑制剂作为食管癌治疗的重要策略之一,其与传统的新辅助治疗方案相结合,为食管癌治疗带来了新的希望。在这篇综述中,将对局部晚期食管癌新辅助治疗策略的研究进展及所存在的问题进行总结。
Surgery is the preferred treatment for patients with resectable esophageal cancer,but for some patients with locally advanced esophageal cancer,neoadjuvant therapy makes tumor resection possible while reducing the risk of local recurrence and distant metastasis.Based on the results of several randomized clinical trials,neoadjuvant therapy can improve the overall survival rate of patients with locally advanced resectable esophageal cancer.Therefore,neoadjuvant the rapy is recommended as the standard of care for patients with locally advanced resectable esophageal cancer.However,the specific regimen of neoadjuvant therapy for patients with different histological types of esophageal cancer remains controversial.In addition,immune checkpoint inhibitors,as one of the important strategies for esophageal cancer treatment,offer new hope for esophageal cancer treatment when combined with traditional neoadjuvant regimens.In this review,the research progress and problems of neoadjuvant treatment strategies for locally advanced esophageal cancer will be summarized.
作者
高鑫
李庆新
胡尕伟
GAO Xin;LI Qingxin;HU Gawei(The 940th Hospital of Joint Logistic Support Force of Chinese People's Liberation Army,Gansu Lanzhou 730050,China)
出处
《现代肿瘤医学》
CAS
北大核心
2023年第21期4083-4088,共6页
Journal of Modern Oncology
基金
全军后勤科研计划项目重大项目(编号:ALJ18J001-7)。
关键词
食管癌
新辅助治疗
化疗
放化疗
免疫治疗
esophageal cancer
neoadjuvant therapy
chemotherapy
radiotherapy
immunotherapy
